The co-primary efficacy endpoints were the change from baseline to Week 12 in ( 1 ) percentage of parabasal cells in the maturation index ( MI ) , ( 2 ) percentage of superficial cells in the MI , ( 3 ) vaginal pH , and ( 4 ) severity of vaginal dryness .